O

Ondine Biomedical Inc
LSE:OBI

Watchlist Manager
Ondine Biomedical Inc
LSE:OBI
Watchlist
Price: 8.65 GBX 1.76%
Market Cap: 34.9m GBX
Have any thoughts about
Ondine Biomedical Inc?
Write Note

Ondine Biomedical Inc
Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Ondine Biomedical Inc
Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
O
Ondine Biomedical Inc
LSE:OBI
Revenue
CA$1.2m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Titan Medical Inc
TSX:TMD
Revenue
$950k
CAGR 3-Years
-64%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Profound Medical Corp
TSX:PRN
Revenue
$9m
CAGR 3-Years
1%
CAGR 5-Years
22%
CAGR 10-Years
N/A
Opsens Inc
TSX:OPS
Revenue
CA$48.4m
CAGR 3-Years
18%
CAGR 5-Years
15%
CAGR 10-Years
20%
Theralase Technologies Inc
XTSX:TLT
Revenue
CA$920.6k
CAGR 3-Years
-5%
CAGR 5-Years
-5%
CAGR 10-Years
-3%
MedMira Inc
XTSX:MIR
Revenue
CA$412.6k
CAGR 3-Years
-42%
CAGR 5-Years
-5%
CAGR 10-Years
-17%
No Stocks Found

Ondine Biomedical Inc
Glance View

Market Cap
34.9m GBX
Industry
Health Care

Ondine Biomedical, Inc. operates as a life sciences company that develops photodisinfection-based therapies to address drug-resistant infections. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2021-12-06. The firm is focused on developing products that utilizes its light-activated technology, primarily for the healthcare-associated infection (HAI) market. Photodisinfection provides a spectrum of antimicrobial efficacy without encouraging the formation and spread of antibiotic resistance. The company offers solution in Steriwave Nasal Decolonization (ND) and SurgENT. Steriwave ND provides a spectrum antimicrobial providing targeted decolonization. SurgENT is a tool for cleaning and irrigating the paranasal sinuses. The intrasinus balloon design directs irrigant circumferentially around the sinus walls, maintaining debridement pressure.

OBI Intrinsic Value
4.24 GBX
Overvaluation 51%
Intrinsic Value
Price
O

See Also

What is Ondine Biomedical Inc's Revenue?
Revenue
1.2m CAD

Based on the financial report for Dec 31, 2023, Ondine Biomedical Inc's Revenue amounts to 1.2m CAD.

What is Ondine Biomedical Inc's Revenue growth rate?
Revenue CAGR 1Y
89%

Over the last year, the Revenue growth was 89%.

Back to Top